{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:22:06Z","timestamp":1790043726423,"version":"4.0.1"},"reference-count":26,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Taliglucerase alfa (Protalix Biotherapeutics, Carmiel, Israel) is a novel plant cell\u2013derived recombinant human \u03b2-glucocerebrosidase for Gaucher disease. A phase 3, double-blind, randomized, parallel-group, comparison-dose (30 vs 60 U\/kg body weight\/infusion) multinational clinical trial was undertaken. Institutional review board approvals were received. A 9-month, 20-infusion trial used inclusion\/exclusion criteria in treatment-naive adult patients with splenomegaly and thrombocytopenia. Safety end points were drug-related adverse events: Ab formation and hypersensitivity reactions. Primary efficacy end point was reduction in splenic volume measured by magnetic resonance imaging. Secondary end points were: changes in hemoglobin, hepatic volume, and platelet counts. Exploratory parameters included biomarkers and bone imaging. Twenty-nine patients (11 centers) completed the protocol. There were no serious adverse events; drug-related adverse events were mild\/moderate and transient. Two patients (6%) developed non-neutralizing IgG Abs; 2 other patients (6%) developed hypersensitivity reactions. Statistically significant spleen reduction was achieved at 9 months: 26.9% (95% confidence interval [CI]: \u221231.9, \u221221.8) in the 30-unit dose group and 38.0% (95% CI: \u221243.4, \u221232.8) in the 60-unit dose group (both P &lt; .0001); and in all secondary efficacy end point measures, except platelet counts at the lower dose. These results support safety and efficacy of taliglucerase alfa for Gaucher disease. This study was registered at www.clinicaltrials.gov as NCT00376168.<\/jats:p>","DOI":"10.1182\/blood-2011-07-366955","type":"journal-article","created":{"date-parts":[[2011,9,7]],"date-time":"2011-09-07T00:37:37Z","timestamp":1315355857000},"page":"5767-5773","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":173,"title":["Pivotal trial with plant cell\u2013expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease"],"prefix":"10.1182","volume":"118","author":[{"given":"Ari","family":"Zimran","sequence":"first","affiliation":[{"name":"Gaucher Clinic, Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einat","family":"Brill-Almon","sequence":"additional","affiliation":[{"name":"Protalix Biotherapeutics, Carmiel, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Chertkoff","sequence":"additional","affiliation":[{"name":"Protalix Biotherapeutics, Carmiel, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Petakov","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology, Diabetes and Metabolic Disorders, Belgrade University Medical School, Belgrade, Serbia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Blanco-Favela","sequence":"additional","affiliation":[{"name":"Department of Hematology, Centro M\u00e9dico Nacional Siglo XXI, M\u00e9xico City, M\u00e9xico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Terreros","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Centro M\u00e9dico Nacional Siglo XXI, M\u00e9xico City, M\u00e9xico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio E.","family":"Solorio-Meza","sequence":"additional","affiliation":[{"name":"Hospital de Especialidades No. 1, Le\u00f3n, M\u00e9xico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Amato","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mount Sinai Hospital, Toronto, ON;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Duran","sequence":"additional","affiliation":[{"name":"Department of Hematology, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorina","family":"Giona","sequence":"additional","affiliation":[{"name":"Department of Hematology, Universit\u00e0 degli Studi La Sapienza, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Heitner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Witwatersrand, Johannesburg, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rambam Health Care Campus, Haifa, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Miguel Servet, Hospital Universitario, Zaragoza, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Hematology, Royal Free Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Park","sequence":"additional","affiliation":[{"name":"Target Health Inc, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mici","family":"Phillips","sequence":"additional","affiliation":[{"name":"Gaucher Clinic, Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Elstein","sequence":"additional","affiliation":[{"name":"Gaucher Clinic, Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheona","family":"Altarescu","sequence":"additional","affiliation":[{"name":"Gaucher Clinic, Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mali","family":"Szleifer","sequence":"additional","affiliation":[{"name":"Protalix Biotherapeutics, Carmiel, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Hashmueli","sequence":"additional","affiliation":[{"name":"Protalix Biotherapeutics, Carmiel, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Aviezer","sequence":"additional","affiliation":[{"name":"Protalix Biotherapeutics, Carmiel, Israel;"},{"name":"Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"21","key":"2019111808462187400_B1","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher's disease.","volume":"324","author":"Barton","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111808462187400_B2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann Intern Med"},{"issue":"8963","key":"2019111808462187400_B3","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0140-6736(95)91038-7","article-title":"Replacement therapy with imiglucerase for type 1 Gaucher's disease.","volume":"345","author":"Zimran","year":"1995","journal-title":"Lancet"},{"issue":"2","key":"2019111808462187400_B4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease.","volume":"90","author":"Starzyk","year":"2007","journal-title":"Mol Genet Metab"},{"issue":"12","key":"2019111808462187400_B5","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.21280","article-title":"A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase.","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am J Hematol"},{"key":"2019111808462187400_B6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease.","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin Hematol"},{"key":"2019111808462187400_B7","first-page":"iii","article-title":"The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.","volume":"10","author":"Connock","year":"2006","journal-title":"Health Technol Assess"},{"issue":"2","key":"2019111808462187400_B8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/GIM.0b013e3181928f6a","article-title":"Dosing enzyme replacement therapy for Gaucher disease: older, but are we wiser?","volume":"11","author":"Sidransky","year":"2009","journal-title":"Genet Med"},{"issue":"3","key":"2019111808462187400_B9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jama.288.3.358","article-title":"The continuing unethical conduct of underpowered clinical trials.","volume":"288","author":"Halpern","year":"2002","journal-title":"J Am Med Assoc"},{"issue":"1","key":"2019111808462187400_B10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcmd.2009.09.006","article-title":"Force Majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.","volume":"44","author":"Hollak","year":"2010","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"2019111808462187400_B11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bcmd.2009.12.001","article-title":"Recommendations for treating patients with Gaucher disease with emerging enzyme products.","volume":"44","author":"Cox","year":"2010","journal-title":"Blood Cells Mol Dis"},{"issue":"16","key":"2019111808462187400_B12","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMp0906922","article-title":"Drug shortages and public health.","volume":"361","author":"Steinbrook","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111808462187400_B13","doi-asserted-by":"crossref","first-page":"e4792","DOI":"10.1371\/journal.pone.0004792","article-title":"A plant-derived recombinant human glucocerebrosidase enzyme\u2013a preclinical and phase I investigation.","volume":"4","author":"Aviezer","year":"2009","journal-title":"PLoS One"},{"issue":"5","key":"2019111808462187400_B14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","article-title":"Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.","volume":"5","author":"Shaaltiel","year":"2007","journal-title":"Plant Biotechnol J"},{"issue":"5875","key":"2019111808462187400_B15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.320.5875.473","article-title":"Is the drought over for pharming?","volume":"320","author":"Kaiser","year":"2008","journal-title":"Science"},{"issue":"6","key":"2019111808462187400_B16","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s10545-008-0868-z","article-title":"Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry.","volume":"31","author":"Fairley","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2019111808462187400_B17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bcmd.2010.10.009","article-title":"Measurement of spleen and liver volumes using MRI in a multi-center trial on treatment-na\u00efve patients with Gaucher disease before and during enzyme-replacement therapy.","volume":"46","author":"Bracoud","year":"2011","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"2019111808462187400_B18","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2214\/ajr.179.4.1790961","article-title":"Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter.","volume":"179","author":"Maas","year":"2002","journal-title":"Am J Roentgenol"},{"issue":"23","key":"2019111808462187400_B19","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","article-title":"Phase 1\/2 and extension study of velaglucerase alfa (gene-activated human glucocerebrosidase) replacement therapy in adults with type 1 Gaucher disease: 48-month experience.","volume":"115","author":"Zimran","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111808462187400_B20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcmd.2007.02.008","article-title":"A pharmacokinetic analyis of a novel enzyme replacement therapy with gene-activated(R) human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease.","volume":"39","author":"Zimran","year":"2007","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"2019111808462187400_B21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.","volume":"26","author":"Cox","year":"2003","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2019111808462187400_B22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9343(94)90042-6","article-title":"Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment.","volume":"97","author":"Zimran","year":"1994","journal-title":"Am J Med"},{"issue":"3","key":"2019111808462187400_B23","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2005-12-5072","article-title":"Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis.","volume":"108","author":"de Fost","year":"2006","journal-title":"Blood"},{"key":"2019111808462187400_B24","first-page":"1065","article-title":"Lipid storage diseases.","volume-title":"Williams Hematology","author":"Zimran","year":"2010","edition":"8th ed"},{"issue":"2","key":"2019111808462187400_B25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","article-title":"Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1.","volume":"11","author":"Grabowski","year":"2009","journal-title":"Genet Med"},{"issue":"6","key":"2019111808462187400_B26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10545-010-9175-6","article-title":"Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy.","volume":"33","author":"Stein","year":"2010","journal-title":"J Inherit Metab Dis"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/22\/5767\/1345307\/zh804811005767.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/22\/5767\/1345307\/zh804811005767.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T09:44:16Z","timestamp":1574070256000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/22\/5767\/29159\/Pivotal-trial-with-plant-cellexpressed-recombinant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,24]]},"references-count":26,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2011,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-07-366955","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,24]]}}}